Christian Henrik Tange
Direktor/Vorstandsmitglied bei KDev Investments AB
Ursprung des Netzwerks ersten Grades von Christian Henrik Tange
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
| Public Company | Financial Conglomerates | 23 | |
Karolinska Development AB (Private Equity)
 Karolinska Development AB (Private Equity) Investment ManagersFinance Karolinska Development AB (Private Equity) (Karolinska Development) is a Venture Capital firm, a subsidiary of Karolinska Development AB founded in 2003. The firm is headquartered in Solna.
10
| Operating Division | Investment Managers | 10 |
AGC Biologics A/S
 AGC Biologics A/S Pharmaceuticals: MajorHealth Technology AGC Biologics A/S provides contract process development and biopharmaceuticals manufacturing services worldwide. It specializes in delivering custom solutions for the scale-up and the cGMP manufacture of protein-based therapeutics for pre-clinical, clinical trials, and commercial production. Its services include cell line development, bioprocess development, formulation, and analytical testing. The company was founded by Peter Vilby, Mads Laustsen, Thomas Sandal, and Morten Munk in 2001 and is headquartered in Soeborg, Denmark.
9
| Subsidiary | Pharmaceuticals: Major | 9 |
| Public Company | Packaged Software | 4 | |
KDev Investments AB
 KDev Investments AB BiotechnologyHealth Technology KDev Investments AB engages in research, sales, and development in the fields of medicine, biotechnology, pharmaceuticals, and medical technology. It also owns and manages investments of companies in the fields of medicine. Its portfolio will include both early and clinical stage pharmaceutical assets, as well as some technology assets. The company was founded on January 10, 2012 and is headquartered in Solna, Sweden.
3
| Subsidiary | Biotechnology | 3 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Christian Henrik Tange
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Akinion Pharmaceuticals AB
 Akinion Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Akinion Pharmaceuticals AB operates as a holding company that focuses on the development of pharmaceutical for the treatment of acute myeloid leukemia. It develops, markets, and sells a product based on Biovitrum’s anti leukemia kinase inhibitor research. It is a drug development that manufactures a lead candidate drug, AKN-028, which is a small molecule kinase inhibitor. The company was founded by Vendela Parrow in 2009 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chief Executive Officer Corporate Officer/Principal Chairman | |
Aprea Therapeutics AB
 Aprea Therapeutics AB Pharmaceuticals: MajorHealth Technology Aprea Therapeutics AB operates as a holding company that provides research performed at Karolinska Institutet. It focuses its activities on discovery and development of novel anticancer compounds targeting the tumor suppressor protein. Its product has been tested in a Phase I/II dose escalating safety study in patients with refractory hematological malignancies or prostate carcinoma. It pursues the development of an anticancer drug, APR-246, which has p53-based mechanism for patients with ovarian cancer. The company was founded by Klas Gosta Wiman, Galina Selivanova, Vladimir Bykov, Wenjie Bao, Natalia Issaeva, and Staffan Strömblad in 2003 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member Chief Executive Officer | |
| Karolinska Institutet | College/University | Corporate Officer/Principal Corporate Officer/Principal Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
Modus Therapeutics AB
 Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Chairman Director/Board Member Director/Board Member | |
KDev Oncology AB
 KDev Oncology AB Miscellaneous Commercial ServicesCommercial Services KDev Oncology AB offers research and development of new cancer treatments. It provides know-how in the field of oncology. The company was founded by David Jern on July 14, 2005 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Chairman Director/Board Member Chief Executive Officer Director/Board Member | |
| MODUS THERAPEUTICS HOLDING AB | Biotechnology | Chairman Director/Board Member Director/Board Member | |
| KD Incentive AB | Director/Board Member Director/Board Member Director/Board Member | ||
| OREXO AB | Pharmaceuticals: Major | Chief Executive Officer Director of Finance/CFO Director of Finance/CFO | |
Umecrine Cognition AB
 Umecrine Cognition AB Pharmaceuticals: MajorHealth Technology Umecrine Cognition AB develops pharmaceuticals against neurological disorders in the central nervous system. The firm focuses on the development and commercialization of novel therapeutics to treat Hepatic Encephalopathy in patients with liver disease. The company was founded by Torbjörn Bäckström in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Chairman Director/Board Member Director/Board Member | |
| PROMIMIC AB | Medical Specialties | Corporate Officer/Principal Director/Board Member Director/Board Member | |
| KCIF Fund Management AB | Director/Board Member Chief Executive Officer Director/Board Member | ||
| NEWRON PHARMACEUTICALS S.P.A. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| NOVO NORDISK A/S | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Royal Swedish Academy of Engineering Sciences
 Royal Swedish Academy of Engineering Sciences Miscellaneous Commercial ServicesCommercial Services The Royal Swedish Academy of Engineering Sciences (IVA) is an organization that brings together around 1,300 academy members and 250 companies to bridge the gap between academia, business, and politics. The non-profit company is based in Stockholm, Sweden. The Swedish company's aim is to work towards people's ability to contribute positively to society. The organization runs an internship program called Tekniksprånget, which gives young people in Sweden the opportunity to test the engineering profession through a four-month paid internship. The program has been running since 2012 and aims to inspire more people to choose a higher technical education. The CEO of the company is Björn O. Nilsson. | Miscellaneous Commercial Services | Corporate Officer/Principal Corporate Officer/Principal | |
| OSSDSIGN AB | Medical Specialties | Director/Board Member Director/Board Member | |
| ORPHAZYME A/S | Pharmaceuticals: Major | Chairman Director/Board Member | |
| University of Lund | College/University | Corporate Officer/Principal Graduate Degree | |
KDev Exploratory AB
 KDev Exploratory AB Miscellaneous Commercial ServicesCommercial Services KDev Exploratory AB provides drug discovery solutions. It performs discovery research in various therapeutic areas, such as screening in oncology, neuroscience, lead finding, characterization in inflammation and angiogenesis/age-related macular degeneration. The company was founded by David Jern in 2000 and is headquartered in Solna, Sweden. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer | |
ClanoTech AB
 ClanoTech AB Pharmaceuticals: MajorHealth Technology ClanoTech AB is a holding company that develops drugs for the treatment of cancer and macular degeneration. Its lead candidate is an inhibitor of the alpha5beta1-integrin receptor which is present in fibroblast and on vascular endothelial cells. Its Alpha5beta1-integrin is strongly up-regulated in fibroblast when switching to the fibrotic state and in scars after glaucoma surgery. Its strategy spans from therapeutic areas with high commercial potential as wet Age Regulated Macular Degeneration to ophthalmology niche indications with orphan drug opportunity such as developing advent in glaucoma surgery techniques. The company was founded by Yihai Cao in 2006 and is headquartered in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Monitor Clipper Partners LLC
 Monitor Clipper Partners LLC Investment ManagersFinance Monitor Clipper Partners LLC (Monitor Clipper Partners) is a private equity firm founded in 1998 by Michael Bell, Robert Calhoun, Mark Thomas and Kevin Macdonald. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Founder Private Equity Investor | |
| University of Copenhagen | College/University | Doctorate Degree Doctorate Degree | |
Arctic Asset Management AS (Sweden)
 Arctic Asset Management AS (Sweden) Investment ManagersFinance Arctic Asset Management AS (Sweden) (AAM-Sweden) is the Sweden-based investment management arm of Arctic Asset Management AS, ultimately owned by Arctic Securities AS in Norway. The firm was founded in 2016 and is headquartered in Stockholm. AFM-Sweden manages portfolio of Nordic equities, Nordic fixed income and Global Life Science – through mutual funds and discretionary mandates for institutional clients, family offices, investment companies and private clients. | Investment Managers | Founder Analyst-Equity | |
| SYNACT PHARMA AB | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member | |
| NEOS AB | Medical Specialties | Chairman Director/Board Member | |
| University of Oxford | College/University | Doctorate Degree Undergraduate Degree | |
| ABLYNX | Biotechnology | Chairman Director/Board Member | |
| Chalmers University of Technology | College/University | Graduate Degree Chairman | |
| Technical University of Denmark | College/University | Undergraduate Degree Corporate Officer/Principal | |
| VIVESTO AB | Pharmaceuticals: Generic | Director of Finance/CFO Chairman | |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Pharmaceuticals: Major | Chairman Chief Operating Officer | |
| GALECTO, INC. | Pharmaceuticals: Major | Chairman Chief Operating Officer | |
| MOLMED S.P.A. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Caerus Consulting AS
 Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Pharmaceuticals: Major | Chairman Chief Executive Officer | |
Athera Biotechnologies AB
 Athera Biotechnologies AB Pharmaceuticals: MajorHealth Technology Athera Biotechnologies AB operates as a biopharmaceutical company which focuses on developing targeted anti-inflammatory biological candidate drugs and companion diagnostics. It has a proprietary program the fully human antibody PC-mAb. The frim develops a biomarker and companion diagnostic CVDefine® kit. Its PC-mAb is a fully human monoclonal antibody which neutralizes a key driver of vascular inflammation, phosphorylcholine, which targets market of reducing secondary cardiovascular events, focusing on high-risk patients with low anti-PC levels. The company was founded by Johan Frostegard in 2002 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
Forendo Pharma Oy
 Forendo Pharma Oy Pharmaceuticals: MajorHealth Technology Forendo Pharma Oy provides novel pharmaceutical treatments for endometriosis and low testosterone levels. Its product fispemifene is the first selective estrogen receptor modulator designed only for men, which helps for the treatment of symptoms of low testosterone, in phase II clinical studies in men with secondary hypogonadism; fispemifene has normalized the low testosterone levels. Its 17HSD1-inhibitor focuses on endometriosis, is a potent and selective lead compounds demonstrated in vivo proof of efficacy in disease model of endometriosis. The company was founded by Risto Arvo Sakari Lammintausta in 2013 and is headquartered in Turku, Finland. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
SBL Vaccin AB
 SBL Vaccin AB Pharmaceuticals: MajorHealth Technology SBL Vaccin AB manufactures and distributes vaccines. Its products are used for the treatment of polio, diarrhoea, and cholera diseases. The company distributes products to the healthcare centers, hospitals, schools, and industrial healthcare units. SBL Vaccin was founded in 1957 and is located in Solna, Sweden. | Pharmaceuticals: Major | Director/Board Member | |
| SCIBASE HOLDING AB (PUBL) | Medical Specialties | Director/Board Member | |
Svenska Vaccinfabriken Produktion AB
 Svenska Vaccinfabriken Produktion AB BiotechnologyHealth Technology Svenska Vaccinfabriken Produktion AB develops vaccines and immunotherapies to prevent and treat life-threatening diseases. The company is based in Stockholm, Sweden. The Swedish company was founded by Matti Sällberg, Margaret Chen, Jens Bäck, Lars Frelin. Richard Bethell has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
| Uc Research AB | Director/Board Member | ||
| Gonzaga University | College/University | Undergraduate Degree | |
| BRAIN+ A/S | Packaged Software | Chairman |
Statistik
International
| Schweden | 34 |
| Dänemark | 9 |
| Vereinigte Staaten | 4 |
| Italien | 3 |
| Vereinigtes Königreich | 2 |
Sektoral
| Health Technology | 31 |
| Consumer Services | 8 |
| Commercial Services | 7 |
| Finance | 4 |
| Technology Services | 2 |
Operativ
| Director/Board Member | 317 |
| Chairman | 97 |
| Corporate Officer/Principal | 93 |
| Chief Executive Officer | 49 |
| Independent Dir/Board Member | 42 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Gunnar Magnus Modee Persson | 51 |
| Ping Tse | 43 |
| Viktor Drvota | 41 |
| Bo Jesper Hansen | 34 |
| Sten Gunnar Otto Skolling | 32 |
| Khalid Islam | 29 |
| Torbjørn Bjerke | 27 |
| Karl Härfstrand | 23 |
| Jim van Heusden | 22 |
| Henrijette Richter | 21 |
| Claes Glassell | 21 |
| Carl Johan Bertil Sundberg | 21 |
| Thomas Balland | 20 |
| Terje Kalland | 20 |
| Gustavo Mahler | 16 |
- Börse
- Insiders
- Christian Henrik Tange
- Unternehmensverbindungen
